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Infectious Complications in Renal
Transplant Recipients
Ravi Parasuraman, Jerry Yee, Vanji Karthikeyan, and
Ramon del Busto
Post– kidney transplant infection is the most common life-threatening complication of long-term
immunosuppressive therapy. Optimal immunosuppression, in which a balance is maintained between prevention of rejection and avoidance of infection, is the most challenging aspect of posttransplantation care. The study of infectious complications in immunologically compromised recipients is
changing rapidly, particularly in the fields of prophylactic and preemptive strategies, molecular
diagnostic methods, and antimicrobial agents. In addition, emerging pathogens such as BK polyomavirus and West Nile flavivirus infections and the introduction of newer immunosuppressive agents
that constantly change the risk profiles for opportunistic infections has added layers of complexity to
this burgeoning field. Although remarkable progress has been made in these disciplines, comprehensive understanding of the clinical manifestations of infections remains limited, and the standardization of prophylaxis, diagnosis, and treatment of most infections is yet inadequately defined. The
long-term goal for optimal care of transplant recipients, with respect to infection, is the prevention
and/or early recognition and treatment of infections while avoiding drug-related toxicities.
© 2006 by the National Kidney Foundation, Inc.
Index Words: Transplantation; Infections; Immune Suppression

K

idney transplantation is considered the
treatment of choice for patients with endstage renal disease, and, presently, 1-year patient and graft survival rates are 95% to 97% and
89% to 95%, respectively.1 Despite such success,
transplant recipients remain vulnerable to several infectious complications that are largely determined by the net state of immunosuppression, environmental exposures, and breaches in
mucocutaneous barriers. Optimal immunosuppression, whereby balance is maintained between rejection and infection, is the most challenging aspect of posttransplantation care.
We contend that a facile appreciation of the
key concepts delineated hereafter is essential
to optimizing the management of infectious
complications in transplant recipients:
1. The first step is identification and eradication of infections before transplantation.2,3
2. Adequate screening of the donors for
transmissible infections is important beFrom the Divisions of Nephrology and Hypertension, and
Infectious Disease, Henry Ford Health Systems, Detroit, MI
Address correspondence to Raviprasenna Parasuraman,
MD, Henry Ford Health Systems, Division of Nephrology and
Hypertension, 2799 West Grand Blvd, CFP-2, Detroit, MI
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3.

4.

5.

6.

cause reactivation of infection(s) under the
influence of induction immunosuppression is a major problem.
Evaluation for and provision of prophylaxis against particular infections in highrisk situations (eg, seropositive cytomegalovirus [CMV] donor with a seronegative
recipient) can prevent serious infection
and complications.
Defining other high-risk situations in
which infections produce substantial morbidity, in order that prospective monitoring or preemptive/prophylactic therapy
can be initiated (eg, lymphocyte-depleting
antibody therapies [Thymoglobulin, SangStat Medical Corp, Fermont, Calif], intravenous immunoglobulins, plasma exchange, and anti-CD 20 [Rituximab,
Genentech Inc, San Francisco, Calif]) antibody therapy is critical.
Acknowledgement of the potential for insidious clinical manifestations of active infection in immunocompromised recipients, which may present explosively and
leave an abbreviated period for effective
management. Such situations require aggressive management with broad spectrum coverage for various infections.
Transplant recipients with serious infections require careful review and analysis
of their immunosuppressants, with possi-
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ble reduction or discontinuation in lifethreatening situations.
7. Detailed knowledge of pharmacokinetic
and pharmacodynamic interactions between immunosuppressive and antimicrobial agents is required to prevent deleterious drug interactions and to appropriately
recommend drug dose adjustments.
In addition to these 7 general concepts,
knowledge of 2 specific areas, the “net state of
immunosuppression” and a “timetable of infections posttransplantation” is crucial for optimal management of infections.

Net State of Immunosuppression
The net state of immunosuppression (NSI) of
a recipient can be determined from the analysis of several factors.3 The most important
factor is the nature of the immunosuppressive
regimen, including doses of agents, durations
of their employment, and the temporal sequence of drugs used, including induction
therapy. Other variables that may contribute
to NSI include prolonged neutropenia, breach
in mucocutaneous barriers, and the presence
of uncontrolled metabolic abnormalities (eg,
diabetes, uremia, and malnutrition). Infections with immunomodulating viruses such
as CMV, human herpesvirus 6 (HHV-6), and
human immunodeficiency virus (HIV) are
highly significant in terms of their ability to
mitigate native immune responses (ie, downregulation). Notably, nearly 90% of infections,
especially opportunistic fungal infections, occur in the presence of immunomodulatory
viral replication. Finally, the age of the recipients also adds to the NSI that may significantly affect the outcome in elderly patients.

Timetable of Infection
Posttransplantation
The posttransplantation interval is the next
important area critical to evaluation of infections because different infections prevail at
different times after transplantation. Although the introduction of newer immunosuppressants and antimicrobial prophylaxis
has altered the timetable of infections, opportunistic infections are still rare during the first
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month after transplantation, despite induction
therapies and greater levels of immunosuppression. This observation implies that ongoing immunosuppression (net state of immunosuppression) is the most important factor
that fosters opportunistic infections.
Three categories of infection occur during
the initial posttransplantation month. The first
is largely related to technical problems, including surgical wound infections, urinary
tract infections, vascular access infections, and
pneumonia.4,5 The second category constitutes a priori recipient infections, which are
exacerbated by immunosuppression. The last
and relatively rare category is represented by
donor-transmitted infections. Infections stemming from immunomodulatory viruses, including CMV, Epstein Barr virus (EBV),
HHV-6, hepatitis B virus (HBV), hepatitis C
virus (HCV), and HIV generally proceed 1 to
6 months posttransplantation. As described,
such infections may significantly contribute to
the net state of immunosuppression and invite opportunistic infection, even in the absence of significant environmental exposure.
Beyond 6 months, approximately 80% of recipients are treated by low maintenance doses
of immunosuppression and are primarily at
risk for various community-acquired infections.
Remaining transplant recipients have
chronic viral infections or remain at substantial risk for opportunistic infections because of
overimmunosuppression. These individuals
may require antimicrobial prophylaxis indefinitely.2,5

Urinary Tract Infections
Urinary tract infection (UTI) is the most common bacterial infection in kidney transplant
recipients, with an incidence of 35% to 79% in
the absence of antibiotic prophylaxis.6,7 With
widespread use of prophylaxis, the incidence
of UTI has decreased significantly.8 –10 Most
UTIs occur within the first 3 months after
transplantation, and the major risk factor is
the presence of a urethral catheter. Other risk
factors include a protracted duration of dialysis before transplantation, female gender,
duration of catheterization, vesicoureteral reflux, polycystic kidney disease with recurrent
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UTIs, diabetes mellitus, chronic viral infections, and increased urinary aluminum excretion.11 In addition, many centers routinely implant vesicoureteral stents that facilitate the
risk of infection.
The causative organisms are similar to
those causing UTI in the general population,
but resistant pathogens such as extendedspectrum ␤-lactamase–producing Klebsiella,
vancomycin-resistant Enterococcus spp, Pseudomonas aeruginosa, and Candida spp have all
emerged as significant pathogens. In addition,
opportunistic infections caused by BK polyomavirus, CMV, Mycoplasma hominis, Corynebacterium urealyticum, and Microsporidium can
also occur. UTI is an important cause of bacteremia in the kidney transplant recipient, and
60% of bacteremias originated from foci of
infection in and around the revised urinary
tract.12 Half of bacteremic UTIs are associated
with technical complications related to surgery such as ureteral leak, stricture, or perinephric hematoma.
More recently, Abbott et al13 in a review of
33,479 kidney transplant recipients in the
United States Renal Data System database
showed that the urinary tract was the source
of infection in one third of patients hospitalized with septicemia. In contrast to UTIs that
occur within the first 3 months, UTIs that
occur after 6 months posttransplantation have
a lower rate of pyelonephritis, bacteremia or
relapses and respond well to conventional 10to 14-day courses of antimicrobial treatment.4,7,14 UTIs that appear in this late time
period in association with bacteremia or recurrent infections warrant investigation for
anatomic and/or functional abnormalities.
Treatment of active UTI should be guided
by results of antimicrobial susceptibility testing. The most frequently used antimicrobials
are trimethoprim-sulfamethoxazole (TMPSMX) and ciprofloxacin, and aminoglycosides
should be avoided if feasible because of their
synergistic nephrotoxicity with tacrolimus
and cyclosporine. The duration of therapy is
controversial and principally based on expert
opinion.15 UTIs occurring in the first 4 to 6
months require prolonged antibiotic therapy
for up to 6 weeks,7 but others advocate standard courses of therapy (10-14 days), reserving prolonged therapy for patients with re-

lapsing infection or when prostatitis is
suspected.7,14,16 Late infections because of
their “benign” nature can usually be treated
for 10 to 14 days. The efficacy of short-course
therapy (single dose or 3 days) has not been
studied rigorously in kidney transplant recipients and is not recommended.16 The management of asymptomatic UTI remains controversial
and
is
considered
largely
unsuccessful.16 –18 Others posit treatment for
asymptomatic infections only during the first
month after transplantation. Lastly, asymptomatic candiduria may be the only microbiological manifestation of disseminated candidiasis and generally requires treatment.19
Although some parties recommend antimicrobial prophylaxis for UTI, no discernible
impact on overall graft or patient survival has
been shown,15,16 and the exact duration of
treatment, optimal agent(s), and antimicrobial
dosing have not been determined. TMP-SMX
remains the most frequently used drug for
prophylaxis and is associated with fewer febrile hospital days and a reduction of UTIs
and other bacterial infections compared with
placebo.9 In addition, TMP-SMX utilization
has virtually eliminated pneumocystis pneumonia (PCP) and reduced the infection rate
from Nocardia, Listeria, and Toxoplasma. In patients with TMP-SMX intolerance, an alternative agent is ciprofloxacin, which is better
tolerated and at least as effective as TMP-SMX
for UTI prevention.10 In our center, we use
TMP-SMX prophylactic therapy for 6 to 12
months after transplantation. Lastly, in patients with recurrent UTIs, anatomic abnormalities, or neurogenic bladder, an indefinite
course of therapy has been advised.

Skin and Soft-Tissue Infections
Skin and soft-tissue infections (SSTIs) in the
kidney transplant recipient are frequently
caused by unusual pathogens and may herald
serious systemic infection. Although pyogenic
bacteria such as Streptococcus pyogenes or
Staphylococcus aureus cause most SSTIs, almost
any organism may be causative. Infections
caused by opportunistic pathogens have been
reported, including fungi (Cryptococcus, Scedosporium, Aspergillus, zygomycetes, dermatophytes and dematiaceous fungi), herpes sim-
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plex virus, varicella-zoster, papilloma virus,
nontuberculous mycobacteria (M cheloneae
and M abscessus), Nocardia spp, and even algae
such as Prototheca.20 It is important, therefore,
to obtain biopsies of skin lesions for appropriate staining and cultures, especially in patients unresponsive to conventional antibacterial therapy.

Surgical Wound Infections
Improvement in surgical techniques and the
use of antibiotic prophylaxis has reduced the
incidence of wound infections to just 1% to 2%
after kidney transplantation.20 The most common etiology of SSTIs is S aureus, but S epidermis, gram-negative bacilli, Candida spp, and
Mycoplasma hominis are also pathogenic.20
Wound infections can be a serious problem,
especially if these involve the perinephric
space.20 The risk profile includes urinary leak,
hematoma, obesity, diabetes, reoperation
through a previous incision, prolonged bladder catheterization, prior peritoneal dialysis,
and the use of mycophenolate mofetil in comparison to azathioprine.21 In an evaluation of
2,013 kidney transplant recipients, obesity
was found to be the most important risk factor
for deep infections, and reduced graft survival
was associated with the presence of wound
infections.22

Pneumonia
Pneumonia occurring within the first 30 days
of transplantation is usually nosocomially acquired and caused by gram-negative bacteria
or S aureus. Pneumonias attributable to opportunistic pathogens such as CMV, PCP, and
Nocardia occur 1 to 6 months posttransplantation; however, more recent implementations
of prophylactic therapy have substantively reduced the frequencies of these infections.
Conventional pathogens such as Streptococcus
pneumoniae, Legionella, Hemophilus influenzae,
and bacteria associated with aspiration have
become relatively more common, and these
typically manifest more than 6 months after
transplantation. In addition, community-associated viral pneumonia caused by influenza,
parainfluenza, respiratory syncytial virus, and
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adenovirus have become more frequently recognized pathogens.20
The risk of active tuberculosis in transplant
recipients is relatively greater than in the general population and must always be considered in the differential diagnosis of pneumonia in transplant recipients. Occasionally,
interstitial pneumonia is manifested as a drug
side effect and has been associated with rapamycin. Kidney transplant recipients with
pneumonia require early and aggressive diagnostic studies such as computerized chest tomography, bronchoalveolar lavage, and lung
biopsy, with the institution of specific therapy
to reduce morbidity and mortality.

Central Nervous System Infections
Central nervous system (CNS) infections in
kidney transplant recipients are frequently
caused by opportunistic pathogens such as
Cryptococcus neoformans, Listeria monocytogenes, Nocardia asteroides, and the herpes
group of viruses (CMV, herpes simplex virus
1 and 2, varicella-zoster virus, and HHV-6).20
With the use of prophylactic TMP-SMX, the
incidence of Nocardia, Listeria, and Toxoplasma
infections has decreased significantly. The
highest risk for CNS infection occurs between
1 to 6 months after tranplantation, with the
exception of cryptococcal disease, which frequently occurs after the sixth month posttransplantation. In addition to acute, subacute, and chronic meningitis or encephalitis,
CNS infections may manifest as an intracranial mass lesion or as progressive dementia.5
Acute meningitis is usually caused by Listeria monocytogenes, whereas subacute and
chronic meningitis is usually the product of
Cryptococcus neoformans infection and less frequently of an M tuberculosis, Nocardia, Listeria,
Histoplasma, or Coccidioides infection. Spaceoccupying brain lesions may be caused by
Nocardia, Aspergillus, zygomycetes, and Toxoplasma. Progressive dementia with or without
other neurologic deficits may be related to
progressive multifocal leukoencephalopathy
because of patient’s virus or infections from
herpes simplex virus, CMV, EBV, and, occasionally, as a side effect of cyclosporine or
tacrolimus therapy.5 It must be emphasized
that clinical presentations of CNS infection in
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transplant recipients are often quite different
from those of nonimmunosuppressed individuals.5 Frequently, there are fewer signs of
meningeal inflammation, and the changes in
the level of consciousness may be subtle.5 Any
unexplained fever and headache should
prompt a neurologic evaluation by brain computed tomography scan or magnetic resonance imaging and lumbar puncture.5

CMV Infection
Antiviral prophylaxis has led to a significant
decrease in the incidence of CMV infection
and disease in kidney transplant recipients.
However, CMV continues to be an important
pathogen. In addition to the characteristic infectious syndromes and direct tissue damage
caused by CMV (pneumonia, colitis, esophagitis, nephritis, and so on), the indirect effects
are just as important and include an increase
in the net state of immunosuppression that
leads to opportunistic infections, allograft
dysfunction and rejection, EBV-associated
posttransplantation lymphoproliferative disorder, and ␤-Herpes virus interactions.5,23 The
most important risk factors for CMV disease
include primary infection from serological
mismatch (donor-positive and recipient-negative CMV status) and use of antilymphocyte
antibodies (ORTHOCLONE OKT3 [Ortho
Biotech Products, Bridgewater, NJ] and antilymphocyte globulin). Other risk factors include the type of organ transplanted (lung ⬎
liver, heart, kidney-pancreas ⬎ kidney); reactivation of HHV-6, HHV-7, and hepatitis C
virus; treatment of acute rejection; stressors
associated with critical illness; and intraoperative hypothermia.23 Until recently, the available techniques for diagnosing CMV were
based on histopathology, viral culture, and
serology.24 However, diagnosis of tissue-invasive disease requires recognition of cytomegalic inclusion bodies, immunohistochemistry, or DNA hybridization techniques14,24,25
and an invasive procedure to obtain samples.
Currently, polymerase chain reaction (PCR) is
the most frequently used test for the diagnosis
of CMV, but results must be critically interpreted in the context of the clinical situation.24
A significant decrement in the frequency of
CMV infection and disease has been achieved

with different preventive antiviral therapies
such as universal prophylaxis, selective prophylaxis, and preemptive therapy.5,23,26 Universal prophylaxis involves the treatment of
all patients before the detection of active CMV
infection. A variant of the universal approach,
“selective prophylaxis,” denotes administration of antiviral therapy to patients at very
high risk of reactivation attributable to heightened levels of immunosuppresion, especially
during utilization of antilymphocyte globulin
and OKT3. Preemptive therapy is given only
to asymptomatic patients in whom active
CMV is detected by the CMV viral load. Naturally, there are advantages and disadvantages to the aforementioned approaches.26,27
Universal prophylaxis has the advantage of
not requiring routine laboratory testing to define risk, and it may also prevent reactivation
of other herpesviruses. However, prolonged
antiviral therapy may induce drug toxicity
and drug resistance, although the risk of either is low. Preemptive therapy and selective
prophylaxis are advantageous because they
reduce exposure to antiviral drugs and reduce
drug costs, toxicity, and possibly emergence
of drug resistance.27,28 Even so, preemptive
therapy is logistically demanding and difficult
and requires costly surveillance testing. Moreover, in the setting of rapid viral replication as
occurs in serologically mismatched patients
(donor CMV positive, recipient CMV negative), CMV disease may occur before identification of risk (ie, positive CMV PCR). Nonetheless, it must be emphasized that
prophylaxis and preemptive therapy are both
effective for preventing CMV disease.29
The American Society of Transplantation
and the Canadian Society of Transplantation
have recently published guidelines for the
prevention of CMV infection and disease in
solid organ transplantation28,30 (Table 1). In
the seronegative recipient with a CMV-positive donor, universal prophylaxis is the preferred methodology because the rapid rise in
viral load renders preemptive strategies logistically difficult. For the CMV-seropositive recipient, prophylaxis or preemptive therapy is
acceptable.
The antiviral agents most commonly used
for prophylaxis include oral or intravenous
ganciclovir and oral valganciclovir, a ganci-
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Table 1. Antimicrobial Prophylaxis in Kidney Transplant Recipients
Infection
UTI

Pneumocystis jiroveci
(formerly P. carinii)

9,10,25,28,30,75

Prophylaxis*

Comments

TMP-SMX (TMP 80 mg/ SMX
400 mg) oral, daily.
Alternative: ciprofloxacin 250
mg oral twice a day
TMP-SMX as above Alternatives:
Dapsone 100 mg oral qd or
aerosolized pentamidine 300
mg once a month or
atovaquone 1500 mg oral qd

Duration of therapy not well
defined. Usually 6–12
months

CMV D-/R-

None

CMV D⫹/R-

Valganciclovir 900 mg oral
everyday for 3 months.
Alternative: ganciclovir oral
(3g/d) or IV (5 mg/kg/d)

D⫹/R⫹ or D-/R⫹

Universal prophylaxis:
Valganciclovir 450–900 mg oral
everyday for 3 months.
Alternatives: ganciclovir oral
(3 g/d) or IV 5 mg/kg/day

Duration of therapy not well
defined. Usually 6–12
months. Prophylaxis
following treatment of
rejection is also
recommended
Consider monitoring PCR or
pp 65 antigen monthly for
3 months and treat
preemptively if positive.
Recipient should receive
CMV negative blood or
leukodepleted blood
products
Universal prophylaxis
preferred over preemptive
therapy. Selective
prophylaxis (valganciclovir
900 mg bid or IV
ganciclovir 5mg/kg every
12 hours) is recommended
in patients receiving ALG
/OKT3 therapy for
rejection
Preemptive therapy:
Valganciclovir 900 mg oral
twice a day. Alternative IV
ganciclovir 5 mg/kg every
12 hours. Duration for at
least 1 week after CMV
viral load is undetectable.
Selective prophylaxis
(valganciclovir 900 mg
twice a day or IV
ganciclovir 5mg/kg every
12 hours) is recommended
for patients receiving
ALG /OKT3 therapy for
rejection

Abbreviations: UTI, urinary tract infection; TMP-SMX, trimethoprim sulfamethoxazole,; D, donor; R, recipient; PCR,
polymerase chain reaction; OKT3, muromonab-CD3; ALG, antilymphocyte globulins.
*All doses are for normal renal function.

clovir prodrug that has significantly better
bioavailability than ganciclovir by the oral
route. The agents used in the treatment of
established CMV disease include intravenous
ganciclovir, valganciclovir, foscarnet, and cidofovir. The largest clinical experience is with
ganciclovir, and because of the significant
nephrotoxicity of foscarnet and cidofovir,
ganciclovir is the preferred antiviral agent for

this indication. The recommended dose of intravenous ganciclovir is 5 mg/kg every 12
hours, with dosage modifications for renal
impairment. Neither oral ganciclovir nor acyclovir is recommended for treatment of established infection. Based on pharmacokinetics
studies, valganciclovir can be used as an alternative to intravenous ganciclovir, but further studies are warranted to validate this
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approach. Treatment should be continued for
at least 1 week after the CMV viral load becomes undetectable. Some experts recommend the use of CMV immune globulin in
cases of severe CMV disease or when hypogammaglobulinemia is present. In addition to
antiviral therapy, immunosuppression should
be reduced if possible. Alternative drugs for
ganciclovir-resistant CMV or ganciclovir-intolerant patients include foscarnet or, less frequently, cidofovir. Foscarnet has been used
alone in full dose or at a reduced dose in
conjunction with reduced dose intravenous
ganciclovir. In patients suspected to have
drug resistance, genotypic testing is recommended.

Hepatitis B and C
Infection control measures and vaccination of
patients have resulted in a reduced incidence
of hepatitis B among kidney transplant recipients, and, currently, most viral hepatitis is
attributable to HCV.31,32 The safety and efficacy of kidney transplantation in hepatitis B
surface antigen (HBsAg)-positive patients remains controversial.14 Increased mortality
from liver disease showed in some but not in
all studies, and when it occurred, it was generally after 10 years or more after transplantation.14 Fornairon et al33 studied a cohort of
151 HBsAg-positive kidney transplant recipients with a median follow-up of 125 months
and revealed a high rate of persistent viral
replication (50%) and reactivation (30%). Serial biopsies in the same study disclosed histological progression (85%) and cirrhosis
(28%), with 23% of cirrhotic patients developing hepatocellular carcinoma. Co-infection
with hepatitis C was significantly associated
with histological worsening, and liver disease
was the leading cause of death in that cohort.
Mathurin et al34 compared patient and
graft survival rates in HBV and HCV-infected
kidney transplant recipients with noninfected
recipients and determined that infection with
HBV or HCV significantly reduced patient
and graft survival. The patient survival 10
years after transplant for uninfected, anti–
HCV-positive and HBsAg-positive recipients
was 80%, 65%, and 55%. Graft survivals were
63%, 49%, and 36%, respectively. In patients

with a pretransplantation diagnosis of cirrhosis, 10-year recipient survival was just 26%.
The authors concluded that biopsy-proven
cirrhosis is a contraindication for kidney-only
transplantation. In such circumstances, combined liver-kidney transplantation should be
considered.35
The treatment of hepatitis B in kidney
transplant recipients is not well defined, and
interferon-␣ is contraindicated because of the
risk of graft rejection.35 Lamivudine appears
to be safe and effective before and after transplantation, although resistance is a frequent
problem. Preemptive or prophylactic treatment with lamivudine before transplantation
may be more beneficial than salvage treatment after hepatic dysfunction ensues after
transplantation.36 In cases of lamivudine resistance, antiviral agents such as adefovir, tenofovir, or entecovir may be considered, although clinical experience with these drugs is
limited. Most importantly, all nonimmune patients should be immunized against hepatitis
B before transplantation.
Hepatitis C is the leading cause of posttransplantation chronic liver disease, and the
prevalence of anti-HCV antibodies in kidney
transplant recipients ranges from 11% to
49%.31,37 Anti-HCV antibodies may occasionally be negative in transplant recipients with
positive HCV RNA, and all patients with liver
disease after transplantation should be tested
for HCV RNA, despite an absence of antiHCV antibodies.31
The impact of HCV infection on the outcome of kidney transplantation is not well
defined. The patient and graft survival rates
are lower in HCV-infected versus noninfected
individuals, with the difference becoming apparent 10 years after transplantation.31,34
Knoll et al38 showed that at 2 years after
transplantation, HCV-positive recipients had
a better survival rate than HCV-positive patients awaiting transplantation, which implies
that chronic HCV infection should not be considered a contraindication to kidney transplantation.35 In a 1993 survey, 89% of transplant centers in the United States accepted
HCV-positive patients for kidney transplantation, and 37% required histological absence of
progressive liver disease.39 The presence of
cirrhosis and advanced age are associated
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with poorer outcomes and transplantation
should be discouraged in these scenarios.34,35
In such patients, combined liver and kidney
transplantation may be considered. In view of
the supply and demand crisis in kidney transplantation, it is considered acceptable to transplant organs from HCV-positive donors into
HCV-positive recipients.31
The antiviral therapy of hepatitis C before
and after kidney transplantation remains
problematic. In patients with end-stage renal
disease, ribavirin is contraindicated because
reduced renal clearance of the agent may induce hemolysis.40 Patients with chronic hepatitis, but without cirrhosis, should be considered for interferon monotherapy, preferably
as its pegylated form, before transplantation.40 However, interferon is not recommended after transplantation because of the
onset of graft rejection that occurs with a
frequency of nearly 50%.31 Lastly, even
though ribavirin monotherapy reduces hepatic enzyme elevations in HCV RNA-positive recipients after 1 year of therapy, there is
no significant alteration of viremia or hepatic
histopathology.41

HIV
Before the highly active antitetroviral therapy
(HAART) era, HIV-infected patients were excluded from solid organ transplantation because of poor prognosis (ie, 3-year patient and
graft survival rates were significantly lower in
HIV-seropositive patients [83% and 53%] compared with seronegative [88% and 73%], respectively42). The introduction of HAART in the
mid-1990s has substantially improved the survival of HIV-infected patients, and a recent evaluation of United States Renal Data System data
discovered that HIV-infected recipients had improved survival compared with HIV-uninfected
recipients; the difference was not statistically
significant.43 A multicenter study of 23 HIVinfected kidney transplant recipients with the
following eligibility criteria: pretransplantation
CD4 ⫹ T-cell counts greater than 200 mL, undetectable HIV RNA, absence of opportunistic
infections, and 6 months or more of HAART44
disclosed 1-year recipient and graft survival
rates similar to HIV-negative recipients. Consequently, the authors contended that kidney
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transplantation should be offered to selected
HIV-infected patients. One important concern
in the management of HIV-infected transplant
recipients is the pharmacokinetic interactions
between immunosuppressive agents and antiretrovirals, emphasizing the importance of a
well-coordinated multidisciplinary team with
expertise in transplantation, HIV medicine, and
pharmacology.45

Polyomavirus Infection
BK virus (BKV), a polyomavirus infection in
adults, is seen with seroprevalence rates as
high as 60% to 80%.46 – 48 The infection rates in
kidney transplant recipients varies between
10% and 60%, and most of these infections
result from reactivation of latent virus from
renal tubular epithelial cells, although they
remain asymptomatic in nearly 90% of patients.49 –51 The clinical manifestation of BKV
disease may include interstitial nephritis, cystitis, and/or ureteral stenosis, and the reported prevalence of BKV-induced nephropathy is 1% to 8%.52–54
The median time to develop BKV disease is
approximately 9 to 14 months, and the most
common clinical manifestation is allograft
dysfunction.55–57 The definitive diagnosis of
BKV disease requires kidney biopsy, showing
viral inclusions with little inflammation in the
early stages and mononuclear cell infiltrates
with tubulitis at later stages. Infected epithelial cells show enlarged nuclei, with basophilic
or amphophilic intranuclear viral inclusions.58
Experience with DNA PCR screening of either
urine or plasma is limited; however, quantitative rather than qualitative DNA is more
likely to be clinically useful. Because there is
no definitive treatment available at present,
the optimal management of BKV disease appears to be judicious reduction in immune
suppression with possible elimination of calcineurin inhibitors, in conjunction with active
surveillance for rejection. Although the antiviral agent cidofovir has shown some promise
when combined with lowered immunosuppression in small studies, its nephrotoxic side
effect may limit its overall utility.54 Some have
reported limited success with the use of leflunomide. Overall, the prognosis for graft
survival is poor, and several institutions have
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reported a 1% to 4% graft loss related to BKV
disease.52 Successful retransplantation after
graft loss from BKV disease has been reported, usually after a 6- to 12-month hiatus
from immunosuppression.59

EBV Infection
EBV infection is quite common in the general
population, and most individuals remain
asymptomatic. Primary EBV infection induces
a mononucleosis-type syndrome with lymphocytosis, pharyngitis, or lymphadenopathy.
The clinical syndromes of EBV infection can
range from a benign polyclonal B-cell infectious mononucleosis-like syndrome to malignant monoclonal lymphoma. Because the virus replicates readily in the oropharyngeal
epithelium, it is commonly transmitted
through saliva. Primary infection can also occur through organ transplantation. EBV infection of B lymphocytes frequently results in a
latent infectious state that may manifest as
overt B-lymphocyte proliferation.60 – 62 EBV
plays a central role in the pathogenesis of
posttransplantation lymphoproliferative disease (PTLD), and its incidence ranges from 1%
to 3%.2 The most clearly defined risk factors
for PTLD are primary EBV infection (donor
positive/recipient negative) that increases the
risk for PTLD by 10- to 76-fold, increases the
net state of immunosuppression, and enhances the risk for coinfection by other immunomodulatory viruses.63 The clinical management of PTLD depends on disease stage, and
immune reconstitution is universally favored
for these patients. Thus, the first step in the
management of PTLD is reduction of patients’
immunosuppression as much as feasible.
Other therapeutic options, including anti–Bcell therapy (anti-CD20 antibodies; Rituximab), chemotherapy, and irradiation are required, depending on the clinical situation,
particularly for the most malignant forms of
monoclonal B-cell lymphoma.

Human Herpes Virus Infections (HHV6, HHV-7, and HHV-8)
HHV-6 and HHV-7 are homologus to CMV,
and seropositivity is observed in more than 90%
of adults. However, the role of these viral infec-

tions is ill defined. HHV-6 has been associated
with many clinical syndromes including myelosuppression, encephalitis, hepatitis, and interstitial pneumonitis. Coinfection by HHV-6 and
CMV viruses is common and postulated to promote symptomatic CMV disease. These immunomodulatory viruses may also increase a
recipient’s susceptibility to opportunistic infections.64 – 66
Diagnosis of HHV-6 and HHV-7 infections
is based on qualitative and quantitative molecular assays, immunohistochemistry, and by
mononuclear cell culture, whereas the mainstay of treatment is reduction in immunosuppression. Antivirals such as ganciclovir and
cidofovir have been shown to be effective in
some observations. HHV-8 is associated with
Kaposi sarcoma and transplantation-associated Kaposi sarcoma occurs in 0.2% to 5% of
kidney transplant recipients, depending on
ethnicity and the net state of immunosuppression. Treatment characteristically involves immunosuppression reduction in addition to
chemotherapy.

West Nile Virus Infection
The West Nile Virus (WNV) was recently
shown to transmit through organ transplantation, in which a single donor was responsible
for infection in 4 recipients.67 It appears that
when exposed to this infection, transplant recipients are at higher risk than the general
population for meningoencephalitis. Diagnosis of WNV infection requires a high index of
clinical suspicion and subsequent confirmation by serological or molecular testing. Reduction in immunosuppression is the only
treatment option at present, and all donors
from endemic areas should be tested for
WNV.

Fungal Infections
Kidney transplant recipients have the lowest
rate of fungal infection among solid organ
transplant recipients. Acknowledged risk factors for fungal infections include exposure to
pathogens, the net state of immunosuppression, glucocorticoid steroid usage, the presence of immunomodulatory viral infections,
prolonged antimicrobial courses of therapy,
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metabolic derangements favoring fungal
growth (uncontrolled diabetes), interruption
of host barriers (eg, intravenous catheters),
indwelling urinary catheters, and longer dialysis vintage antedating transplantation.68 –70
Among the fungal infections, Candida and Aspergillus are the most common. Candida infection is quite common and usually manifests
from the time of immediate posttransplantation up to 6 months later, whereas Aspergillus
infections present themselves somewhat later.
With the exception of crytococcosis, fungal
infections occurring 6 months after transplantation are rare, unless immunosuppression
was intensified to prevent allograft rejection
and/or significant environmental exposure to
a pathogen has taken place.
Candida species account for 90% to 95% of
all invasive fungal infections in kidney transplant recipients. Typical clinical manifestations of Candida species include infections related to vascular accesses, the urinary tree,
and deep wound infections. Disseminated infections account for less than 5%70,71 of these
infections. Treatment options for candidemia
include fluconazole, which is the most frequently used anitmicrobial, amphotericin B
plus fluconazole, and the echinocandins (eg,
caspofungin or micafungin). The treatment
success rate is significantly higher with a combination of amphotericin B and fluconazole, in
comparison to fluconazole alone (69% v
56%).72 Caspofungin is considered to be as
effective as amphoericin B with fewer drugrelated adverse events.73
The angioinvasive Aspergillus species and
their spores are ubiquitous. This fungus is
frequently isolated from hospital ventilation
systems, especially during periods of construction or renovation. However, community
environmental exposures also occur. Spore inhalation is the principal mode of infection
acquisition, with lung and upper respiratory
tract being the most common sites of infection.
Pulmonary involvement is seen in up to 90%
of solid organ transplant recipients with invasive aspergillosis, and central nervous system
involvement is not uncommon. However, if
the organism breaches the confines of the respiratory tract and invades the vasculature,
tissue infarction, hemorrhage, and dissemination will ensue. CMV prevention strategies
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and induction protocols with antilymphocyte
antibodies may significantly raise the incidence of Aspergillus infections. The treatment
of choice for invasive aspergillosis is voriconazole. Alternative antifungals consist of amphotericin B, itraconazole, and caspofungin. A
consensus for the duration of therapy does not
exist, and so patients often receive long-term
maintenance therapy.
Cryptococcal species can cause subacute
and chronic meningitis, and disseminated disease involving skin or osteoarticular tissues
are not uncommon. Recently, the incidence of
emergent fungal infections that includes scedosporium, zygomycosis (Absidia, Mucor, and
Rhizopus), and Fusarium are increasing and
account for more than 10% of all opportunistic
fungal infections. Like Aspergillus species, the
zygomycetes can invade blood vessels causing hemorrhagic necrosis, vascular thrombosis, and tissue infarction. Risk factors for infections by these organisms include treatment
of rejections, especially with glucocorticosteroids, prolonged neutropenia, ketoacidosis,
kidney failure, and the presence of foreign
bodies. The common clinical manifestation is
pulmonary zygomycosis, but extrapulmonary
infections include rhinocerebral, CNS, genitourinary, musculoskeletal, gastrointestinal, and
cutaneous infections. Molds such as Aspergillus species can be seen concomitantly in pulmonary cavitary lesions and may represent a
reservoir of infection.
Fusarium, a teleomorphic/anamorphic filamentous fungi of which there are more than
20 species, can produce infection in neutropenic and immunocompromised recipients.
The portals of entry are generally the respiratory tract and skin. Characteristic skin lesions
are a clue to the diagnosis. Fusariosis syndromes include sinopulmonary infection,
skin/soft-tissue infection, fungemia, and disseminated disease. Fusarium is more commonly isolated from blood cultures than Aspergillus species, which are rarely cultured
from blood. Tissue biopsy procedures are
strongly recommended to ascertain a diagnosis. Notably, the histological diagnosis may be
confused with the hyphal elements of an Aspergillus spp.
Scedosporium apiospermum, a dimorphic
asexual fungus, commonly manifests with
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Table 2. Screening of Donors Before Kidney Transplantation77
Serologic Test

Action/Comments

CMV serology
HIV-1, HIV-2 ⫹
HTLV I/II ⫹
Hepatitis C ⫹
HBsAg ⫹ or HBcAb IgM ⫹
HBsAb ⫹
HBcAb IgG ⫹

Use to determine prophylaxis in conjunction with recipient serology
Exclude from organ donation
Generally excluded from organ donation
Usually reserve organ for HCV ⫹ recipient
Exclude from organ donation
Generally safe for organ donation
Small risk of transmission; used for vaccinated recipients or with
HBV prophylaxis with HBIG and/or lamivudine
Consider PCR monitoring if recipient seronegative (mismatch is a
risk factor for PTLD)
Not a contraindication to donation. Treat recipient with benzathine
penicillin
Screening of live donors, blood products recommended

EBV ⫹
Syphilis (RPR) ⫹
West Nile virus

Abbreviations: CMV, cytomegalovirus; HIV, human immunodeficiency virus; HTLV, human T cell lymphotropic virus;
HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface antibody; HBIG, hepatitis
B immune globulin; EBV, Epstein-Barr virus; RPR, rapid plasma reagin; PTLD, post-transplant lymphoproliferative
disease; ⫹, positive test.

skin lesions that later progress to invasive or
nodular pulmonary disease. This infection is
found in lung transplant recipients and has
also been reported in kidney transplant recipients. It has even recurred during retransplantation. S apiospermum is resistant to most antifungal agents including amphotericin B;
however, some success has been achieved
with voriconazole.74
Coccidioides immitis and Histoplasma capsulatum are geographically restricted fungi—Coccidioides in the southwestern United States and
Histoplasma in the central United States (ie, the
Gulf Coast to the Great Lakes regions). New
disease may be acquired while traveling
through endemic areas or transmitted via organ donation. The clinical consequences of
endemic mycoses include pneumonia and disseminated infections involving mucocutaneous, musculoskeletal, CNS, and gastrointestinal tract systems. All transplant recipients
with evidence of remote granulomatous lesions on chest radiographs should be evaluated for mycobacterial and fungal infections.
Patients with a history of either epidemiological exposure and/or with history of coccidioidomycosis or histoplasmosis should receive prophylaxis with an “azole” chronically.
The diagnosis of coccidioidomycosis or histoplasmosis is generally guided by serologic
testing and tissue demonstration of microorganisms. Lastly, all forms of the disease can
result in allograft dysfunction and death.

Strategies for Prevention of Infections
Fortunately, many infectious complications
after kidney transplantation are preventable.
Preventive strategies include counseling of
patient and family members regarding risk
factors for infections,75 donor and recipient
screenings before transplantation, antimicrobial prophylaxis for recipients, and immunizations of patients, their household members,
and health care workers. A complete history
should be obtained focusing on prior infectious diseases and exposures, antibiotic allergies, immunizations, traveling or prior residence in areas endemic for specific infections
(eg, mycoses [coccidioidomycosis and histoplasmosis] and/or parasitic diseases [malaria, strongyloidiasis, schistosomiasis]), use
of illicit drugs, high-risk sexual behavior(s),
and incarceration.14 Antimicrobial prophylaxis of recipients and recommendations regarding the screening of donors and recipients before transplantation are summarized in
Tables 1, 2, and 3. It should be emphasized
that prophylaxis for PCP and CMV should be
started immediately after transplantation and
also whenever antilymphocyte antibodies are
used for rejection. Children who are awaiting
kidney transplantation should receive, in addition to the standard primary vaccine series,
varicella vaccination, if not immune.76 In the
adult patient, every effort should be made to
update immunizations before transplantation
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Table 3. Screening of Recipient Before Kidney Transplantation77
Test
CMV
HIV 1, HIV2 ⫹
Hepatitis C ⫹

Hepatitis B
VZV
PPD ⫹
Other serologic testing:

Action/Comments
Use to determine prophylaxis in conjunction with donor serology
Selected patients may be considered for transplantation (see text)
Consider for transplant unless advanced liver disease. Consider
treatment with interferon before transplant. Combined liver and
kidney transplantation should be considered in the presence of
liver cirrhosis
If seronegative, vaccinate before transplant
If seronegative and exposed to VZV, prophylaxis with VZIG and
acyclovir recommended. Consider immunization before transplant
Treat for latent TB infection (INH⫹ Vitamin B6 for 9 months) Need
to rule out active disease
Test candidates from endemic areas for histoplasma, coccidioides,
strongyloides, trypanosomal infections

Abbreviations: CMV cytomegalovirus; HIV, human immunodeficiency virus; VZV, varicella-zoster virus; VZIG, varicellazoster immunoglobulin; PPD, purified protein derivative; ⫹, positive test.

because the antibody titers achievable in
transplant recipients are often suboptimal. In
addition, because of the risk of disseminated
disease, the use of live virus vaccines (measles-mumps-rubella and varicella) is contraindicated after transplantation. Recommendations on immunizations of adults awaiting
kidney transplantation are summarized in Table 4.
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